Veracyte Q4 Revenues Rise 51 Percent; Projects Steep Increase in 2014 | GenomeWeb

NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Tuesday that revenues for its fourth quarter rose 51 percent year over year.

The South San Francisco, Calif.-based firm recorded $6.8 million in revenues for the three months ended Dec. 31, 2013, up from $4.5 million in the year-ago fourth quarter. In a statement, Veracyte President and CEO Bonnie Anderson said, "We saw increases in fine needle aspiration sample volumes and cash collections during the fourth quarter, which is traditionally our strongest quarter."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.